SS-31
Barth syndrome · Body weight ≥30 kg · US Forzinity label
SS-31 is elamipretide. This reference covers the US Forzinity label for Barth syndrome, not general mitochondrial wellness. Barth syndrome · Body weight ≥30 kg · US Forzinity label.
Reviewed 2026-10-17. A source reference, not a personal treatment plan. Discuss treatment decisions with a qualified clinician.
Dose reference
| LABEL CONTEXT | Dose | Frequency | Context |
|---|---|---|---|
| Label dose · ≥30 kg | 40 mg | Once daily | Source |
| Adult eGFR <30, no dialysis | 20 mg | Once daily | Renal adjustment applies to adults not receiving dialysis. Source |
For adults on dialysis and paediatric patients with renal impairment, the label does not establish a regimen. These are renal-function branches, not escalation steps.
Source context
The accelerated approval concerns muscle strength in Barth syndrome at body weight of at least 30 kg. It is a narrow indication, not a general longevity approval.
Reading the dose correctly
For adults on dialysis and paediatric patients with renal impairment, the label does not establish a regimen. These are renal-function branches, not escalation steps.
Download the chart
Further reading
References
Does the reference apply to other formulations?
Only the product, preparation and route named here are covered. A shared substance name does not establish an equivalent amount for another formulation.
Where can I read the wider evidence?
The linked myPeptides SS-31 monograph covers the mechanism, human and preclinical evidence, and important distinctions between related substances.